Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) based on published randomized controlled trials (RCTs).